Cardiff Oncology Announces First Patient Enrolled in Randomized First-Line RAS-mutated Metastatic Colorectal Cancer Trial
Brief Summary
Cardiff Oncology announced that the first patient has been dosed in the Phase 2 trial for RAS-mutated metastatic colorectal cancer, comparing ONVANSERTIB plus standard of care (SOC) against SOC alone, with initial results expected in mid-2024.
Impact of The News
The event is situated at the company and product level within the economic and financial domain.
Brief Introduction:
Cardiff Oncology, in collaboration with Pfizer, is conducting a Phase 2 clinical trial (CRDF-004) to evaluate the efficacy of ONVANSERTIB combined with standard of care (SOC) against SOC alone in treating patients with RAS-mutated metastatic colorectal cancer. This marks an important step in potentially advancing treatment options for a specific subset of colorectal cancer patients. Initial results from the trial are anticipated to be released in mid-2024.
Impact Transmission Path:
Company Impact:
Cardiff Oncology: Successful trial outcomes could enhance Cardiff Oncology’s market position and lead to increased valuation due to potential advancements in cancer treatment protocols.
Pfizer: As the company executing the trial, positive results could bolster its reputation in oncology research and development, potentially translating into financial gains and further collaboration opportunities.
Product Impact:
ONVANSERTIB: If proven effective, ONVANSERTIB could become a significant player in the treatment of RAS-mutated metastatic colorectal cancer, offering a novel therapeutic option and driving sales growth.
Overall, the trial’s progress and results could influence Cardiff Oncology’s strategic direction and partnerships, impacting its financial and operational performance.
